SCHEMBL4318329

SCHEMBL4318329

CC(C)(C)OC(=O)N1CCC[C@@H]1COc1ccc(Oc2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.49
PRMT5 O14744 1/20 0.48
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
ALOX5AP P20292 3/20 0.46
CHEK2 O96017 1/20 0.46
LTA4H P09960 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
FEN1 P39748 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318335 1.00 GPR119 (0.49) GPR119PRMT5CHRNB4CHRNA3ALOX5AP
SCHEMBL4324225 0.94 LTA4H (0.48) GPR119ALOX5APLTA4H
SCHEMBL4324219 0.94 LTA4H (0.48) GPR119ALOX5APLTA4H
SCHEMBL938055 0.91 ABHD6 (0.50) GPR119CHRNB4CHRNA3ALOX5APFEN1
SCHEMBL27936838 0.91 ABHD6 (0.50) GPR119CHRNB4CHRNA3ALOX5APFEN1
SCHEMBL938053 0.91 ABHD6 (0.50) GPR119CHRNB4CHRNA3ALOX5APFEN1
SCHEMBL4325378 0.89 CHRNB1 (0.50) GPR119PRMT5CHRNB4CHRNA3ALOX5AP
SCHEMBL4325384 0.89 CHRNB1 (0.50) GPR119PRMT5CHRNB4CHRNA3ALOX5AP
SCHEMBL4316198 0.88 FFAR1 (0.49) GPR119ALOX5APCHEK2LTA4HFEN1
SCHEMBL4313801 0.88 FFAR1 (0.49) GPR119ALOX5APCHEK2LTA4HFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926708-B1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2014-06-18 EP disclosed
US-8598359-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2013-12-03 US disclosed
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF (IS) 2009-06-25 US disclosed
US-7402684-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENECTICS EHF. (IS) 2008-07-22 US disclosed
EP-1926708-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION Decode Chemistry, Inc. (US) 2008-06-04 EP disclosed
WO-2007040681-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2007-04-12 WO disclosed
WO-2007040682-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF. (IS) 2007-04-12 WO disclosed
US-20070078263-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-04-05 US disclosed
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885PRMT5 3869/4885CHRNB4 3623/4885
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885PRMT5 3869/4885CHRNB4 3623/4885
US-20070078263-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S GPR119 2606/4885PRMT5 3869/4885CHRNB4 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.